• Oncolytics Biotech posted a Q2 net loss of USD 9.44 million, widening from USD 5.28 million a year earlier.
• R&D expense more than doubled to USD 4.26 million, driven by Phase 2 second-line mCRC start-up costs and higher stock-based pay.
• G&A expense rose 87.1% to USD 5.12 million on higher investor relations activity and added legal and tax fees tied to domestication.
• Cash and cash equivalents totaled USD 4.12 million at June 30, 2026; management flagged substantial doubt about going concern.
• Launched REO 033 in March; expects about half of planned sites activated in Q3, with Fast Track designations in mCRC and SCAC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001129928-26-000051), on August 12, 2026, and is solely responsible for the information contained therein.